Anti-CD47 therapy has demonstrated promise preclinically in glioma models and is the only immunotherapy in clinical trials, but its effectiveness will likely be limited due to variable CD47 expression in glioblastoma patients, especially in newly diagnosed cases. This evidence concerns the gene CD47 and glioblastoma.